期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗真菌药物的药物代谢动力学/药效学及其合理应用 被引量：6

原文传递
导出
摘要 抗真菌药物的临床应用越来越广泛，加之多数药物特异性不强，在作用于真菌细胞的同时也易对人体细胞产生毒性作用；此外，临床治疗真菌感染的药物有限，且用药剂量较大、疗程长、不良反应较多及毒性较大，影响了临床应用。近年来新靶向剂型、新作用靶位的药物相继上市，但真正安全有效的为数尚少。掌握各类抗真菌药物的代谢动力学和药效学（PK／PD）特点及不良反应，对于临床合理选择和应用至关重要。
作者 王睿
机构地区 解放军总医院临床药理研究室
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2007年第11期818-820,共3页 Chinese Journal of Tuberculosis and Respiratory Diseases
关键词 药物代谢动力学 抗真菌药物 药效学 临床应用 毒性作用 人体细胞 不良反应 药物特异性
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献12

  • 1Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of Systemic Antifungal Agents. Clin Infect Dis, 2006, 43 Suppl 1 : S28 -S39.
  • 2Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol, 2004,42:4419-4431.
  • 3Alexander BD, PfaUer MA. Contemporary Tools for the Diagnosis and Management of Invasive Mycoses. Clin Infect Dis, 2006, 43 Suppl 1 :S15-S27.
  • 4Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis, 2004, 38 : 161-189.
  • 5Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother, 2003,51:671-681.
  • 6吴绍熙,郭宁如.抗真菌药与药物相互作用研究进展[J].中国新药杂志,2002,11(11):847-849. 被引量：1
  • 7Johnson LB, Kauffman CA. Vorieonazole: a new triazole antifungal agent. Clin Infect Dis, 2003,36:630-637.
  • 8Al-Abdely HM, Alkhunaizi AM, AI-Tawfiq JA, et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol, 2005, 43:91-95.
  • 9Vazquez JA. Anidulafungin: a new echinocandin with a novel profile. Clin Ther, 2005,27:657-673.
  • 10Yan JH, Marino MR, Smith RA, et al. The Effect of Ravuconazole on the Pharmacokinetics of Nelfinavir in Healthy Male. J Clin Pharmacol, 2006,46 : 193-200.

二级参考文献24

  • 1Thye D,Kilfoil T,White K,et al. Anidulfungin:Pharmacokinetics in subjects with mild and moderate hepatic impairment[A].Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy(ICAAC) ASM[C]. Chicago, 2001.
  • 2White RJ, Thyr D. Anidulfungin does not affect the metabolism of cyclosporin by human hepatic microsomes[A]. Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM[C]. Chicago, 2001.
  • 3Thye D, Shepherd RJ,White RJ, et al. Anidulfungin: a phase I study to identify the maximum tolerant dose in healthy volunteers [A]. Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM [C].Chicago,2001.
  • 4Muller SC, Majcher-peszynska J, Hundkowski RG, et al. Fluconazole in anuric patients undergoing continuous-veno-venoushemodilysis(CVVHD), pharmacokinetics and dosage simulation [A].Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM [C]. Chicago,2001.
  • 5Leather HJ, Wingard JR. Characterizing the pharmacokinetics (PK) drug interaction betwenn intravenous itraconazole and iv tacrolimus(FK506) or Ⅳ cyslosporin in allogeneic bone marrow transplant (allobmt) patients [A]. Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM[C]. Chicago, 2001.
  • 6Donnelly JP, Mouton JW, Rhijlevens NMA, et al. Pharmacokinetics of a 14 day course of itrcconazole nanocrystals given intravenously to allogeneic hematopoetic stemcell transplant (HCCP)recipients[A]. Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM [C].Chicago, 2001.
  • 7Tan KKC, Wood N, Weil A, et al. Multiple-dose pharmacokinetics of voriconazole in chronic hepatic impairment[A]. Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy(ICAAC) ASM[C]. Chicago, 2001.
  • 8Walsh T,Arguedas A, Droscoll T, et al. Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administnation[A]. Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy(ICAAC)ASM[C].Chicago, 2001.
  • 9Tan KKC, Brayshaw M, Oakes M. Investigation of the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials [A]. Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy(ICAAC) ASM[C]. Chicago, 2001.
  • 10Wood N, Tan K, Allan R, et al. Effect of voriconazole on the pharmacokinetics of omeprazole [A]. Proceeding of 41th Intersciences conference on Antimicrobial Agents and Chemotherapy (ICAAC) ASM[ C]. Chicago, 2001.

同被引文献26

引证文献6

二级引证文献10

中华结核和呼吸杂志
2007年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部